Press Releases

The U.S. FDA has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors. This decision makes Eli Lilly and...

CytoDyn Inc , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported that it has received Institutional Review Board (IRB) approval to begin its Phase 2 clinical trial for...

Drug discovery software at Southwest Research Institute is expanding the capacity to virtually screen drug compounds for possible treatment of coronavirus and other infectious diseases. SwRI’s Rhodium™ virtual screening tool recently evaluated 2 million drug compounds in a few days,...

Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any...

Spring Bank Pharmaceuticals Inc. said it has entered into a new clinical collaboration with Roche to explore the co-administration of SB 11285, Spring Bank's intravenously-administered stimulator of interferon gene agonist with Roche's PD-L1 checkpoint inhibitor atezolizumab in patients with...

Vir Biotechnology, Inc. and WuXi Biologics announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2. Under the terms of the agreement, the...

Perrigo Company plc and its partner, Catalent Pharma Solutions, announced that the U.S. FDA has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA*. Perrigo is launching a...